Clinical Trials

Clinical Trials

  Section Menu

CIMAvax Vaccine

Roswell Park has launched the first clinical trial in the U.S. to study the CIMAvax-EGF ® vaccine, a lung cancer treatment. Learn more about CIMAvax.

A clinical trial is a study designed to evaluate a promising new medical treatment. It includes research done to evaluate new ways to prevent and diagnose and/or treat cancer. At Roswell Park, up to 50% of our patients are eligible to enter clinical trials. Many types of treatment can be tested including:

  • New ways of preventing cancer such as drugs, diet, and/or exercise
  • New drugs to treat cancer
  • New ways to use existing treatment such as surgery or radiation therapy

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today’s standard treatments were researched and proven by clinical trials done in the past.

Should I participate in a clinical trial? (Learn more about clinical trials from the NCI.)

Recently Opened Clinical Trials

Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
Principal Investigator:
Noyes, Ekaterina
A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)
Principal Investigator:
Levine, Ellis G
MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)
Principal Investigator:
Levine, Ellis G
(B1371012) AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Principal Investigator:
Wang, Eunice S
A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors (CA013-004)
Principal Investigator:
Ernstoff, Marc S
(ARO-021) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Principal Investigator:
Wang, Eunice S
OSCO-P1301 A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Principal Investigator:
Wang, Eunice S
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)
Principal Investigator:
Puzanov, Igor
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Principal Investigator:
Chatta, Gurkamal S
Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous "switching" between flavors (CRoFT_3.1)
Principal Investigator:
Goniewicz, Maciej L
(UTX-TGR-205) A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Principal Investigator:
Hernandez-Ilizaliturri, Francisco J
A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES
Principal Investigator:
George, Saby
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-AXL-ADC) in patients with solid tumors.
Principal Investigator:
Dy, Grace K